Related Experiment Video
Updated: Feb 14, 2026

Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool
Published on: May 27, 2016
Ceritinib efficacy in SMARCA4-deficient NSCLC harboring novel CTNND2 ALK/EML4-ALK fusion: case report
Zhigang Fu1, Gengda Huang2, Jian Xie3
1The Seventh Affiliated Hospital of Southern Medical University, Foshan, China.
Abstract:
SMARCA4-deficient non-small cell lung cancer (SMARCA4-dNSCLC) is an aggressive malignancy with poor prognosis, rarely harboring EGFR, ALK, or ROS1 alterations. We report an advanced SMARCA4-dNSCLC case with brain metastasis exhibiting a novel CTNND2-ALK/EML4-ALK double-fusion. Following platinum-based chemotherapy and brain radiotherapy, next-generation sequencing identified the dual fusions (abundances: 2.6% and 5.2%), confirmed by ALK protein expression. The patient subsequently received ceritinib (750 mg/day). After 3 months, targeted lesions regressed significantly, and progression-free survival exceeded 24 months with ongoing response. This demonstrates efficacy of the ALK inhibitor ceritinib in ALK-rearranged SMARCA4-dNSCLC and underscores the clinical value of genomic-guided therapy.
Insights
SMARCA4-deficient non-small cell lung cancer (SMARCA4-dNSCLC) with a rare double-gene fusion responded well to ALK inhibitor therapy. This genomic-guided treatment led to significant tumor regression and prolonged progression-free survival.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- SMARCA4-deficient non-small cell lung cancer (SMARCA4-dNSCLC) is aggressive with poor prognosis.
- This subtype rarely presents with EGFR, ALK, or ROS1 alterations.
Related Concept Videos
Nuclear Fusion
A helium nucleus has a mass that is 0.7% less than that of four hydrogen nuclei; this lost mass is converted into energy during the fusion. This reaction produces about...
Self-Efficacy
Data Reporting and Recording
Types of Reports I: Hands-off Report
Following are the key components and categories of hand-off reports:
Purpose and Process:
Tagging and Fusion Proteins
SNAREs and Membrane Fusion
SNAREs exist in pairs that symmetrically interact and catalyze the fusion of the lipid bilayers in vesicle and target organelle. v-SNARE in the vesicle membrane are single polypeptide chains that bind to a complementary t-SNARE, composed of 2...

